Quinoline derivative against non-small cell lung cancer

US10307412B2 · kind B2 · utility

Inventors

• Xunqiang Wang · 安丰镇, CN
• Yadong Miu · 安丰镇, CN
• Min Zhou · Suzhou, CN
• Shanchun Wang · 安丰镇, CN
• Ling Yang · Lianyungang, CN
• Wei Shi · 安丰镇, CN

Key dates

• Filing date: Dec 9, 2015
• Grant date: Jun 4, 2019
• Expiry date: Dec 9, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/4866
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.